There is not a standard second line therapy for NEC patients treated with platinum based doublet, nevertheless Temozolamide and Capecitabine (TX) represent a regimen used in this setting, based on small and retrospective series (8). Therefore in our study we recommend that all patients at first progression (even if out of the study) will receive TX (Capecitabine 750 mg/m2 po BID days 1-14 plus Temozolomide 200 mg/m2 po quaque die (QD) days 10-14 q28) in order to homogenize second line treatment. However, second line treatment is chosen by single investigators.